Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.950 -0.010 (-0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst
J.P. Morgan analyst revises outlook on GoodRx Holdings following Q1 earnings, reaffirms Overweight rating and $7 price target. 
Via Benzinga
Demystifying GoodRx Holdings: Insights From 5 Analyst Reviews
Via Benzinga
Why GoodRx Holdings Stock Triumphed on Thursday
Via The Motley Fool
GoodRx’s (NASDAQ:GDRX) Q1 Earnings Results: Revenue In Line With Expectations, Stock Jumps 10.3%
Healthcare tech company GoodRx (NASDAQ:GDRX) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $203 million. The company’s outlook for the full year was close to... 
Via StockStory
Earnings Scheduled For May 7, 2025
Via Benzinga
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Assessing GoodRx Holdings: Insights From 4 Financial Analysts
Via Benzinga
GoodRx Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GoodRx (GDRX) Reports Earnings Tomorrow: What To Expect
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Reasons to Sell GDRX and 1 Stock to Buy Instead
GoodRx’s stock price has taken a beating over the past six months, shedding 30.4% of its value and falling to $4.55 per share. This was partly driven by its softer quarterly results and may have... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
3 of Wall Street’s Favorite Stocks Showing Warning Signs
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
3 Small-Cap Stocks in Hot Water
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
3 Stocks Under $10 Skating on Thin Ice
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
GoodRx (GDRX) Q4 2024 Earnings Call Transcript
GDRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M. 
Via Benzinga
GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next... 
Via StockStory
GoodRx Earnings: What To Look For From GDRX
Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results tomorrow before the bell. Here’s what investors should know. 
Via StockStory
1 Healthcare Stock Primed for Growth and 2 to Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
1 Healthcare Stock Primed for Growth and 2 to Snub
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
Why GoodRx Holdings Stock Was Sinking This Week
The company is growing key fundamentals. However, the improvements weren't enough to impress the market. 
Via The Motley Fool
GoodRx (GDRX) Q3 2024 Earnings Call Transcript
GDRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx (GDRX) Q2 2024 Earnings Call Transcript
GDRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges
GoodRx reported Q2 revenue of $200.61M, a 6% YoY increase. Prescription transactions revenue rose 7%, driven by 8% growth in Monthly Active Consumers. The company expects FY 2024 revenue at the lower... 
Via Benzinga
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.